Meta-analysis · people
Linaclotide beat placebo in IBS-C and chronic constipation trials
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
For people using linaclotide (Linzess) for IBS-C or chronic constipation, this pooled analysis of placebo-controlled trials found about 1 in 7 treated people responded who would not have on placebo.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2013
- Journal
- Clin Gastroenterol Hepatol
What they tested
The team set out to measure how well linaclotide works compared with placebo for adults with irritable bowel syndrome with constipation (IBS-C) or chronic constipation.
How the study was done
A systematic review and meta-analysis of randomized, placebo-controlled trials in adults with IBS-C or chronic constipation. The search found 7 trials, and 6 were pooled into the analysis.

What they found
In IBS-C, most of the 3 trials used the response measure the U.S. Food and Drug Administration recommends: at least 1 more complete spontaneous bowel movement (CSBM) per week, plus a 30% or more drop in worst daily belly pain scores, for 50% of treatment weeks. By that measure, people on linaclotide 290 μg were 1.95 times as likely to respond as those on placebo (relative risk, 95% CI, 1.3-2.9), and 7 people had to be treated for 1 extra responder (number needed to treat, 95% CI, 5-11). In chronic constipation, 3 trials counted a response as more than 3 CSBMs per week plus a gain of at least 1 per week, for 75% of weeks; here the 290 μg dose gave a relative risk of 4.26 (95% CI, 2.80-6.47), with a number needed to treat of 7 (95% CI, 5-8). Across both conditions, belly pain, bloating and overall symptom severity were lower and stool form was better on linaclotide.
What it doesn’t show
The pooled result rests on a small number of trials, and the main IBS-C estimate draws on only some of the IBS-C trials. Linaclotide was compared only with placebo, not with other treatments for constipation.
The paper
Videlock et al. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol. 2013.
The compound
More studies on Linaclotide
- Linaclotide plus PEG improved colonoscopy prep quality in 8 RCTsMeta-analysis · people · 2026
- Linaclotide: bowel prep scores similar to double-dose PEGMeta-analysis · people · 2025
- Linaclotide plus 1 L PEG-Asc: 92% vs 86% adequate prep vs sennaRandomized trial · people · 2025
- Linaclotide raised weekly bowel movements in kids with constipationRandomized trial · people · 2024
- Linaclotide: trend to more bowel movements in kids at higher dosesRandomized trial · people · 2024
- Linaclotide beat placebo for chronic constipation in 12-week trialsRandomized trial · people · 2011
- Every study on Linaclotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.